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Abstract
Background: Previous studies suggest that chemokines (chemotactic cytokines) promote and
regulate neoplastic progression including metastasis and angiogenesis. The chemokine eotaxin-1 is
a powerful eosinophil attractant but also exerts chemotaxis of other leukocytes. Eotaxin-1 has
been implicated in gastrointestinal disorders and may play an important role in colorectal mucosal
immunity.
Patients and methods: The objective of this study was to assess the role of eotaxin-1 in
colorectal cancer (CRC). Levels of eotaxin-1 protein in CRC tissues (n = 86) and paired normal
mucosa were compared after determination by ELISA. Plasma eotaxin-1 levels from CRC patients
(n = 67) were also compared with controls (n = 103) using the same method. Moreover, a TaqMan
system was used to evaluate the -384A>G eotaxin-1 gene variant in CRC patients (n = 241) and in
a control group (n = 253).
Results: Eotaxin-1 protein levels in colorectal tumours were significantly (P < 0.0001) higher than
in normal tissue. Immunohistochemistry revealed eotaxin-1 expression in stromal cells such as
fibroblasts and leukocytes of the CRC tissue. The plasma eotaxin-1 level in CRC patients was lower
compared with controls (P < 0.0001). Patients with tumours classified as Dukes' stage B and C had
lower levels than patients with tumours in Dukes' stage A. We found no difference in genotype
distribution but noted a difference regarding allele distribution (P = 0.036) and a dominance of allele
G in rectal cancer patients.
Conclusion:  The up-regulated eotaxin-1 protein expression in cancer tissue may reflect an
eotaxin-1 mediated angiogenesis and/or a recruitment of leukocytes with potential
antitumourigenic role. We noticed a dominance of the G allele in rectal cancer patients compared
with colon cancer patients that was independent of eotaxin-1 expression.
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Background
Previous studies show that chemokines (chemotactic
cytokines) are important factors promoting leukocyte
attraction to sites of inflammation and cancer [1-3]. Some
of the chemokines may promote and regulate neoplastic
progression including metastasis and angiogenesis [4,5].
In the gastrointestinal tract the intestinal mucosa regulates
trafficking of the leukocytes by chemokines such as
CXCL5, CXCL8 and CXCL12 [6,7]. The chemokine
eotaxin-1 (CCL11) is one member of the eotaxin gene
family (eotaxin-1, eotaxin-2 and eotaxin-3) which is a
group of eosinophil chemoattractants [8]. Eotaxin-1
binds exclusively to the receptor CCR3, which is present
on eosinophils. Basophils, mast cells, Th2 cells, dendritic
cells and endothelial cells also express CCR3 at variable
levels [9-11]. Eosinophil accumulation in the peripheral
blood and tissues is a marker of several diseases such as
viral and parasitic infections, atopic disorders, eosi-
nophilic gastroenteritis and pneumonia [12]. In the gas-
trointestinal tract, eotaxin-1 is expressed in mucosa and it
has been suggested that eotaxin-1 has an important role in
the maintenance of normal eosinophil homeostasis [13].
The expression of eotaxin-1 has been identified in macro-
phages, eosinophils, epithelial cells, endothelial cells,
fibroblasts, malignant epithelial cells and smooth muscle
cells [14-18]. Consequently, eosinophils seem to have the
capacity to generate their own autocrine chemoattractant
factor eotaxin-1 [19].
Eotaxin-1 may play a role in a number of chronic inflam-
matory diseases such as sinusitis, nasal polyposis, rhinitis,
ulcerative colitis and other gastrointestinal disorders
[9,20]. Increased plasma levels of eotaxin-1 have been
shown in coronary artery disease and inflammatory bowel
disease [21,22]. Moreover, it has been suggested that
eotaxin-1 may protect against tumour progression by
recruiting eosinophils with a capacity to release cytotoxic
proteins [14].
Several single nucleotide polymorphisms (SNPs) of the
eotaxin-1 gene have recently been described. One of these,
the -384A>G variant, is located at the promoter region of
the eotaxin-1 gene and has been shown to have functional
effects on eotaxin-1 synthesis. This variant correlated sig-
nificantly with an elevated plasma eotaxin-1 level in asth-
matic patients. It has been postulated that the -384A>G
locus may exert its influence through change in the
eotaxin-1 gene transcription [23].
The aim of the present study was to investigate the rela-
tion of eotaxin-1 protein expression to, and the influence
of the eotaxin-1 gene variant -384A>G on CRC.
Materials and methods
This investigation was approved by the research ethical
committee at the Faculty of Health Sciences, Linköping,
Sweden (Dnr. 98113). Informed consent was obtained
from each subject.
DNA samples
Study materials comprised blood samples obtained from
241 patients undergoing surgical resections for primary
colorectal adenocarcinomas at the Department of Surgery,
Ryhov County Hospital, Jönköping, Sweden. The patient
group represented 123 males and 118 females with a
mean age of 70 years (range 29–93). All tumours were
classified according to Dukes' classification system: stage
A (n = 45), stage B (n = 102), stage C (n = 82), and stage
D (n = 12). The tumours were localized in the colon (n =
121) and rectum (n = 120).
Blood donors (n = 253), from Ryhov County Hospital
with no known CRC history and a normal blood status,
were selected as controls. This group consisted of 133
males and 120 females, with a mean age of 68 years (range
50–83). All blood-controls came from the same geograph-
ical region as the CRC patients and all cases and controls
were of Swedish Caucasian origin. All blood was stored
frozen until DNA was extracted using QIAamp DNA
blood kit (Qiagen, CA, USA).
Plasma samples
Sixty-seven of the CRC patients and 103 blood-control
donors were available for plasma collection. Patient
blood was collected before surgery. All blood, including
that from the control group, was separated by centrifuga-
tion within 1 h. Plasma was removed and stored at -70°C.
The CRC patient group comprised 38 males and 29
females with a mean age of 69 years (range 29–88). The
patient tumours were categorized according to Dukes'
classification; stage A (n = 15), stage B (n = 29), and stage
C (n = 23). Thirty-five tumours were located in the rectum
and 32 in the colon. Controls consisted of plasma from 54
males and 49 females, with a mean age of 61 years (range
55–67).
Tissue samples
Tissue samples available from 86 of the CRC patients were
used in the study. The tumours came from 49 males and
37 females having a mean age of 69 years (range 29–88).
Tumours were collected and classified according to Dukes'
classification system: stage A (n = 16), stage B (n = 37),
and stage C (n = 33). Tumours were localized in the colon
(n = 43) and rectum (n = 43). Tumour tissue and adjacent
normal mucosa (about 5 cm from the tumour) from each
patient were excised and immediately frozen at -70°C
until analysis.World Journal of Surgical Oncology 2007, 5:84 http://www.wjso.com/content/5/1/84
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Frozen tumour tissue and normal mucosa were thawed,
homogenised in ice cold lysis buffer containing PBS (9.1
mM dibasic sodium phosphate, 1.7 mM monobasic
sodium phosphate, 150 mM NaCl, pH = 7.4) and 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulphate (SDS), 100 µg/ml phenylmethylsulpho-
nyl flouride (PMSF), 2 µg/ml aprotinin, 1 mM sodium
orthovanadate and 1 µg/ml leupeptin. The lysate was
placed on ice for 30 minutes and then centrifuged at
13000 g for 10 minutes. Protein content of the superna-
tant fluid was determined for each sample using the Brad-
ford protein assay (Bio-Rad Laboratories, UK).
Eotaxin-1 genotype determination
DNA samples were genotyped using 5'-exonuclease allelic
discrimination assay (Applied Biosystems, USA). TaqMan
SNP genotyping assay was used for analysis of
rs17809012 genotype (Applied Biosystems). Ten-to-fif-
teen ng DNA was amplified in a total volume of 12 µl con-
taining 1× TaqMan Universal PCR master mix (Perkin-
Elmer, Applied Biosystems), including 1× TaqMan SNP
genotyping assays. Amplification was performed using an
initial cycle at 95°C for 20 s followed by 40 cycles at 95°C
for 3 s and 60°C for 30 s. A post-PCR endpoint plate read
was performed on each plate using the 7500 Fast Real
Time PCR system (Applied Biosystems). The manual call-
ing option in the allelic discrimination application ABI
Prism 7500 SDS software version 1.3.1 was then used to
assign genotypes.
ELISA of eotaxin-1
Eotaxin-1 in plasma and tissue was measured using a
commercially available enzyme-linked immunosorbent
assay (ELISA) kit (R&D Systems Europe, UK) following
the manufacturer's instructions. The plasma eotaxin-1
concentration from CRC patients and control subjects was
expressed as picograms per millilitre (pg/ml) and the
eotaxin-1 protein levels of cancer and paired normal tis-
sues from the CRC patients were expressed as picograms
per milligram of protein (pg/mg).
Immunohistochemistry of eotaxin-1
Fourteen tumour samples were available for immunohis-
tochemical staining for determination of the cell type ori-
gin of eotaxin-1 expression. Staining was performed on 4
µm sections from formalin-fixed paraffin-embedded tis-
sue blocks, using a standard protocol. Endogenous perox-
idase activity was quenched by treatment with 3%
hydrogen peroxide for 5 min. Sections were subsequently
incubated with a primary mouse anti-human monoclonal
CCL11/eotaxin-1 antibody (R&D Systems Europe, UK) in
appropriate dilution overnight at 4°C. After rinsing in
TRIS-buffered saline, sections were incubated with sec-
ondary biotinylated goat anti-mouse IgG (Santa Cruz Bio-
technology, USA). Avidin-biotin peroxidase complexes
(Dako Cytomation Denmark) were added, followed by
visualization with 3,3'-diaminobenzidine tetrahydrochlo-
ride (Dako Cytomation). All sections were counterstained
with Mayer's hematoxylin (Histolab Products AB, Swe-
den).
Statistical analysis
Differences in the frequencies of the eotaxin-1 polymor-
phism between CRC patients and the control group and
between clinical data within the CRC subgroup were ana-
lyzed using the Chi-square test. The Hardy-Weinberg
equilibrium was tested for all polymorphisms. Differ-
ences in eotaxin-1 plasma levels between patients and
control subjects were examined using the Mann-Whitney
U test. Differences in eotaxin-1 protein expression
between tumour and normal paired tissues were exam-
ined using the Wilcoxon signed rank test. Statistical anal-
ysis was performed using the SPSS for Windows computer
package (Rel. 14.0, 2005, Chicago: SPSS Inc.). Results
were considered significant at a level of P < 0.05.
Results
Eotaxin-1 genotype
To analyse the influence of eotaxin-1 on colorectal car-
cinogenesis, we investigated the prevalence of promoter -
384A→G gene polymorphism in 241 CRC patients and
253 control subjects using the TaqMan system.
There was no significant difference in genotype distribu-
tion or in allelic frequencies, between CRC patients and
control subjects (Table 1). When subdividing the patients
in groups, colon (n = 121) versus rectum (n = 120), we
noted a weak anomaly (P = 0.065) in genotype distribu-
tion (Table 2). However, we found a significant difference
regarding allele distribution (P = 0.036). When assessing
this difference we noticed a 51.7% (124/240) dominance
of the G allele in rectal cancer patients compared with
42.1% (102/242) in colon cancer patients. When testing
the allele distribution in colon and rectal cancer patients
compared with control subjects respectively we found a
dominance of the G allele in the rectal cancer patients (P
= 0.036). No difference was seen in colon cancer patients
compared with controls (P = 0.73). The genotype and
allelic distributions in CRC patients and the control group
were not associated with clinical characteristics such as
age, gender, or Dukes' stage. All genotype distributions
were in Hardy-Weinberg equilibrium.
Plasma levels of eotaxin-1
Plasma levels of eotaxin-1 were measured by ELISA in 67
CRC patients and 103 healthy control subjects. The
eotaxin-1 plasma concentration was lower (P < 0.0001) in
CRC patients [median 26.2 (range 9.8–74.5) pg/ml] than
in controls [median 48.9 (range 22.6–208) pg/ml] (Figure
1). A significantly lower eotaxin-1 plasma level was notedWorld Journal of Surgical Oncology 2007, 5:84 http://www.wjso.com/content/5/1/84
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in Dukes' stages B (median 24.4 pg/ml) and C (median
25.6 pg/ml) as compared to Dukes' A (median 34.3 pg/
ml) (P = 0.008 and P = 0.011, respectively) (Figure 1). The
plasma levels of eotaxin-1 from CRC patients were not
related to age, gender, tumour location or any eotaxin-1
allele/genotype investigated in this study (data not
shown).
Levels of eotaxin-1 in colorectal tissue
Eotaxin-1 protein concentration was measured by ELISA
in protein-lysates of colorectal cancerous tissues and
matched normal tissues from 86 patients. The levels of
eotaxin-1 protein in cancer tissue [median 17.4 (range 0–
383) pg/mg] were higher when compared to normal tis-
sue [median 9.7 (range 0–153) pg/mg] (P < 0.0001), (Fig-
ure 2). Evaluation of the relative expression (tumour vs.
normal tissue) showed 74.4% (64/86) up-regulation.
There was no correlation between levels of eotaxin-1 pro-
tein in analyzed tissue samples from the CRC patients and
clinical characteristics such as age, gender, tumour loca-
tion, Dukes' stage, or eotaxin-1 allele/genotype deter-
mined in this study (data not shown).
Location of eotaxin-1 expression in CRC tissue
Immunohistochemistry was performed to investigate the
site of eotaxin-1 protein expression. Immunoreactivity
showed heterogenous and focal staining of eotaxin-1 in
tumour tissue and the resection border comprising nor-
mal tissue. The immunoreactivity was localised in stromal
cells with morphological characteristics of fibroblasts, as
well as leukocytes, including lymphocytes and macro-
phages (Figure 3). No staining was observed with second-
ary antibody exclusively (data not shown).
Discussion
Chemokines which regulate leukocyte movement are sug-
gested to play a crucial role in the congregation of lym-
phocytes in the intestine [6,7]. Eotaxin-1 is an eosinophil
chemoattractant, expressed in the gastrointestinal mucosa
by several stromal cells, which can also regulate chemo-
taxis of other cells such as basophils, Th2 lymphocytes
and mast cells [8-10]. Eotaxin-1 seems to play a potential
role in a number of diseases such as gastrointestinal disor-
ders [9] and it has been suggested that eotaxin-1 could
play a protective role against tumour progression [14],
probably as a factor in tumour immune surveillance [22].
Plasma eotaxin-1 concentrations in healthy controls and  CRC patients Figure 1
Plasma eotaxin-1 concentrations in healthy controls and 
CRC patients. CRC patients have significantly lower concen-
trations compared to controls. The plasma eotaxin-1 con-
centrations in Dukes' stage B and C patients were lower 
compared with Dukes' stage A patients. Medians are shown 
by horizontal bars.
Table 2: Genotype and allele numbers of the Eotaxin/CCL11 
gene polymorphism (- 384A → G) regarding to location and 
Dukes stage in CRC
Genotype Allele
A/A A/G G/G A G
Colon (n = 121) 37 66 18 140 102
Rectum (n = 120) 28 60 32 116 124
Colon vs. Rectum: Genotypes overall P = 0.065, Alleles P = 0.036
Table 1: Genotypic and allelic distributions in % (n) of Eotaxin/CCL11 polymorphism in CRC patients and control subjects
Genotype CRC Controls Allele CRC Controls
(n = 241) (n = 253) (n = 482 alleles) (n = 506 alleles)
- 384A →G
A/A 27.0 (65) 30.8 (78)
A 53.1 (256) 56.5 (286)
A/G 52.3 (126) 51.4 (130)
G 46.9 (226) 43.5 (220)
G/G 20.7 (50) 17.8 (45)
CRC patients vs. controls: Not significantWorld Journal of Surgical Oncology 2007, 5:84 http://www.wjso.com/content/5/1/84
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One SNP of the eotaxin-1 gene, -384A>G, has been
showed to have a functional role in regulation of gene
expression, and thus influences the eotaxin-1 synthesis.
The presence of allele G is associated with higher plasma
concentration of eotaxin-1 in asthmatic patients [23]. In
our study, we focused on this SNP and showed that the
genotype distribution and allelic frequency were not sig-
nificantly associated with CRC patients as compared to
controls. We did not detect any association between gen-
otype and eotaxin-1 plasma concentration in plasma sam-
ples. However, we found a significant difference regarding
allele distribution between rectal and colon cancer and
noted a dominance of allele G in rectal cancer patients. In
addition, we have demonstrated the distribution of the
eotaxin-1 gene variant -384A>G in a Swedish population,
for the first time.
Possible differences in the carcinogenesis of colonic and
rectal carcinomas have been reported [24]. Hypotheti-
cally, different mechanisms may be involved in the cancer
susceptibility in colon and rectum depending partly on
allele G.
In diseases with immune and inflammatory response,
such as Crohn's disease and Sjögren's syndrome, the circu-
lating level of eotaxin-1 compared to controls is higher
and lower, respectively [21,25]. In addition, a negative
correlation between the circulating level of eotaxin-1 and
eosinophil counts has been noted in Crohn's disease [21].
We found a significantly lower eotaxin-1 plasma level in
CRC patients than in controls, and this difference
increases with increasing Dukes' stage. Referring to the
studies above [21,25], and our investigation, the findings
indicate that there may be different mechanisms of
immune regulation in different disease entities. Our study
may show an imbalance in production of plasma eotaxin-
1 from eosinophils or endothelial cells in CRC patients,
and that a lower plasma eotaxin-1 level may reflect disease
status of CRC. The discrepancy between tissue and plasma
level ratio of eotaxin-1 in CRC may be explained by a bio-
logical difference that influences the secretion of eotaxin-
1 in CRC tissue.
Using ELISA, we noted a significantly higher expression of
eotaxin-1 protein in cancer tissue in comparison to
matched normal tissue. Evaluation of the relative expres-
sion (tumour vs. normal tissue) showed 74.4% up-regula-
Images of immunohistochemical staining of eotaxin-1 in  colorectal tissue from patients with CRC Figure 3
Images of immunohistochemical staining of eotaxin-1 in 
colorectal tissue from patients with CRC. Eotaxin-1 express-
ing stromal cells in cancer (A) and normal (B) tissue. Magnifi-
cation, × 200.
The eotaxin-1 protein level in cancer tissue was significantly  higher compared to normal paired tissue Figure 2
The eotaxin-1 protein level in cancer tissue was significantly 
higher compared to normal paired tissue. Medians are shown 
by horizontal bars.World Journal of Surgical Oncology 2007, 5:84 http://www.wjso.com/content/5/1/84
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tion. By using immunohistochemistry to determine the
origin of the eotaxin-1 protein expression in CRC patient
tissues we found immunoreactivity localised to stromal
cells such as fibroblasts and leukocytes.
Very few reports have investigated eotaxin-1 expressing
cells in relation to CRC outcome. Higher amount of eosi-
nophilic infiltration of CRC has been reported to be a
favourable prognostic indicator in CRC patients [26,27].
On the other hand, gastric carcinoma with eosinophilia
correlates with unfavourable prognosis [28]. It has been
suggested that eotaxin-1 directly mediates angiogenesis by
CCR3+ endothelial cells [11]. This effect may contribute to
tumour growth and thereby poor prognosis in CRC. Thus,
the role of eotaxin-1 and eosinophilia is not fully evalu-
ated in CRC. We noted a significantly up-regulated
eotaxin-1 level in cancer tissue which may reflect a poten-
tial eotaxin-1 mediated angiogenesis. Alternatively, this
could mediate protection against tumour progress by
recruitment of eosinophils and/or other CCR3+ leukocytes
with an antitumourigenic role.
The pathophysiological significance of the observed up-
regulation remains unclear until basal mechanisms
describing the transcriptional regulation and the signal-
ling pathway of eotaxin-1 expression in CRC are eluci-
dated. To date, little is known with regard to the influence
of eotaxin-1 gene polymorphisms on the levels of eotaxin-
1 in normal and neoplastic human tissues.
Conclusion
We noticed a dominance of the G allele in rectal cancer
patients compared with colon cancer patients that was
independent of eotaxin-1 expression. The -384A>G
eotaxin-1 gene variant may be partly involved in the
pathogenesis of cancer in the rectum and colon. The up-
regulated eotaxin-1 protein expression in cancer tissue
represented by stromal cells may reflect an eotaxin-1
mediated angiogenesis and/or a recruitment of leukocytes
with potential antitumourigenic effect. Finally, the
plasma levels of eotaxin-1 were lower in CRC patients
compared to controls, and the suppression seems to be
more pronounced in severe disease stage.
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